“…In epilepsy patients, without co-morbidities, aPL were distributed as follows: aCL 28.7% vs. 8.1% in HCs (OR: 5.2, 95% CI: 3.2-8.3, p < 0.01; I 2 ¼44%, p ¼ 0.04), more in paediatrics, also more in partial vs. generalized epilepsy, and in Asian vs. Europeans; ab2GPI (screened in 7/14 studies): 11.8% vs. 2.8% in HCs (OR: 3, 95% CI: 1.1-8.1, p ¼ 0.04; I 2 ¼35%, p ¼ 0.16), and was significant in pediatric and African population with epilepsies. 20 Another systematic review about aPL and dementia in the general population included 32 studies, some observational. The aCL prevalence ranged from 5.9% to 31.1% in the general population, 4 studies investigated the prevalence of aPL in patients with cognitive impairment/dementia (small samples, inconsistent aPL profiling, and heterogeneous definition of cognitive damage): overall the prevalence of aPL ranged from 6% to 56.6% in vascular dementia, and aCL, the most tested, was found to be more prevalent and with higher titers in patients with dementia vs. HCs.…”